Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Osterborg

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Seminars in Oncology|June 8, 2004
New erythropoietic proteins: rationale and clinical dataAnders Osterborg
Expert Opinion on Biological Therapy|January 30, 2010
Ofatumumab, a human anti-CD20 monoclonal antibodyAnders Osterborg
Current Treatment Options in Oncology|April 30, 2004
Therapy for mycosis fungoidesJeanette Lundin, Anders Osterborg
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2010
Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemiaSusan O'Brien, Anders Osterborg
Seminars in Hematology|July 23, 2004
Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemiaJeanette Lundin, Anders Osterborg
Medical Oncology (Northwood, London, England)|August 16, 2002
Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemiaAnders Osterborg, Hakan Mellstedt, Michael Keating
British Journal of Haematology|April 9, 2005
Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized studyAnders Osterborg, Yvonne Brandberg, Michael Hedenus
Current Hematologic Malignancy Reports|April 29, 2010
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemiaAnders Osterborg, Claes Karlsson, Jeanette Lundin
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Anemia in multiple myelomaHeinz Ludwig, Gudrun Pohl, Anders Osterborg
Acta Oncologica (Stockholm, Sweden)|September 5, 2008
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov modelSixten Borg, Anna H Glenngård, Anders Osterborg, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Seminars in Oncology|June 8, 2004
New erythropoietic proteins: rationale and clinical dataAnders Osterborg
Expert Opinion on Biological Therapy|January 30, 2010
Ofatumumab, a human anti-CD20 monoclonal antibodyAnders Osterborg
Current Treatment Options in Oncology|April 30, 2004
Therapy for mycosis fungoidesJeanette Lundin, Anders Osterborg
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2010
Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemiaSusan O'Brien, Anders Osterborg
Seminars in Hematology|July 23, 2004
Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemiaJeanette Lundin, Anders Osterborg
Medical Oncology (Northwood, London, England)|August 16, 2002
Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemiaAnders Osterborg, Hakan Mellstedt, Michael Keating
British Journal of Haematology|April 9, 2005
Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized studyAnders Osterborg, Yvonne Brandberg, Michael Hedenus
Current Hematologic Malignancy Reports|April 29, 2010
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemiaAnders Osterborg, Claes Karlsson, Jeanette Lundin
Clinical Advances in Hematology & Oncology : H&O|September 16, 2005
Anemia in multiple myelomaHeinz Ludwig, Gudrun Pohl, Anders Osterborg
Acta Oncologica (Stockholm, Sweden)|September 5, 2008
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov modelSixten Borg, Anna H Glenngård, Anders Osterborg, et al.
Pageof 8